NLS Pharma diabetes therapy gets BIRD Foundation milestone payment
Ticker: NCEL · Form: 6-K · Filed: Jul 17, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: biotech, drug-development, milestone-payment, diabetes
TL;DR
NLS Pharma's diabetes cell therapy gets another cash injection from BIRD Foundation.
AI Summary
On June 17, 2025, NLS Pharmaceutics Ltd. announced that the BIRD Foundation approved an additional milestone payment to Kadimastem and iTolerance for the co-development of their Type 1 Diabetes cell therapy, iTOL-102. This payment signifies continued progress in the diabetes program.
Why It Matters
This milestone payment from the BIRD Foundation indicates continued progress and validation for NLS Pharmaceutics' Type 1 Diabetes cell therapy, potentially accelerating its development.
Risk Assessment
Risk Level: medium — The filing is a routine report of a press release, but the underlying therapy's success is subject to clinical trial outcomes and regulatory approval.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- BIRD Foundation (company) — Approving entity for milestone payment
- Kadimastem (company) — Co-developer receiving milestone payment
- iTolerance (company) — Co-developer receiving milestone payment
- iTOL-102 (product) — Type 1 Diabetes cell therapy
- June 17, 2025 (date) — Date of press release
FAQ
What is the specific amount of the additional milestone payment approved by the BIRD Foundation?
The filing does not specify the exact dollar amount of the additional milestone payment.
What is the purpose of the iTOL-102 therapy?
iTOL-102 is a cell therapy for Type 1 Diabetes.
Which entities are co-developing the Type 1 Diabetes cell therapy with NLS Pharmaceutics?
Kadimastem and iTolerance are co-developing the therapy.
What is the filing date of this Form 6-K?
This Form 6-K was filed on July 17, 2025.
What is the primary business of NLS Pharmaceutics Ltd. according to the filing?
NLS Pharmaceutics Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 17, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).